New drug brings new hope for breast cancer
Triple-negative breast cancer is a particularly strong disease. And now a new drug brings hope for patients with triple-negative breast cancer. A recent study found that the current treatment of TNBC can maintain healthy state within six months and the disease would no longer develop in the state, and the treatment effect is twice that of other treatment options. This is the second innovative treatment in three urgent programs approved by the state. This kind of treatment combines antibody drugs and chemotherapy drugs. It still needs some trials of recombinant human proteins to verify its effect.
“Antibody drugs can find cancer cells. After positioning the cancer cells, they bring the chemotherapy drugs to cancer cells,” said researcher Dr. Aditya Bardia, who was the physician at the Massachusetts General Hospital Cancer Center. “This is a key reason that we were able to improve chemotherapy cancer treatment effect.” The treatment program is called sacituzumab govitecan (an antibody drug conjugate, abbreviated: IMMU-132), which acts like a “smart bomb”.
The antibody takes specific protein marker Trop-2 of TNBC as locating target. The antibody can specifically recognize this protein, ensuring that damage to the surrounding healthy tissue of cancer cells is minimal. “So a stable condition nearly six months is really very important,” Dr. Linda Bosserman says. She is the assistant professor of Hope Clinical Medicine Institute in the California city and was not involved in the study. Bosserman said the researchers found that the drug also can also achieve the efficacy of part of the patient’s potential long-term disease control. If the clinical effect of the drug was confirmed, she added, “Then I would advise patients to take this drug treatment, because it is not only significant in effect, but also show relatively small destructive power. And at the same time, it does not cause major disease symptoms under the cancer treatment, which greatly improves the quality of life for patients.”
The US Food and Drug Administration, which has approved many kinds of drugs targeteing at recombinant rat proteins, believes that this new drug occupies the position of “breakthrough”, accelerating the development of a cancer patient’s treatment device. “The drug may be soon approved by the official sector,” Bardia represented.